Global Shigella Infections (Shigellosis) Pipeline Report 2016 - Review of Anacor Pharma, GSK, Microbiotix, Protein Potential & Visterra & Their Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Shigella Infections (Shigellosis) - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Shigella Infections (Shigellosis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Shigella Infections (Shigellosis) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Shigella Infections (Shigellosis) Overview
  3. Therapeutics Development
  4. Pipeline Products for Shigella Infections (Shigellosis) - Overview
  5. Pipeline Products for Shigella Infections (Shigellosis) - Comparative Analysis
  6. Shigella Infections (Shigellosis) - Therapeutics under Development by Companies
  7. Shigella Infections (Shigellosis) - Therapeutics under Investigation by Universities/Institutes
  8. Shigella Infections (Shigellosis) Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Shigella Infections (Shigellosis) - Products under Development by Companies
  13. Shigella Infections (Shigellosis) - Products under Investigation by Universities/Institutes
  14. Shigella Infections (Shigellosis) - Companies Involved in Therapeutics Development
  • Anacor Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Microbiotix, Inc.
  • Protein Potential, LLC
  • Visterra, Inc.

For more information visit http://www.researchandmarkets.com/research/wk5pk3/shigella

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Infectious Diseases Drugs